1. FDA Issues Warning Letters to 30 Telehealth Firms Over Misleading Claims on Compounded GLP-1 Drugs
The U.S. Food and Drug Administration (FDA) has taken regulatory action against 30 telehealth companies, issuing formal warning letters concerning their marketing and promotion of compounded versions of popular glucagon-like peptide-1 (GLP-1) agonist drugs, such as Ozempic (semaglutide) and Zepbound (tirzepatide). The ...